Naturally Splendid Responds to Health Canada’s Information Request Notice

Vancouver, British Columbia – TheNewswire – October 16, 2020 – Naturally Splendid Enterprises Ltd. (“Naturally Splendid”, “NSE” or “the Company”) (FRANKFURT:50N) (TSXV:NSP) (OTC:NSPDF) has responded through their joint venture Plasm Pharmaceutical (“Plasm”) to Health Canada’s Information Request Notice (“IRN”). The questions as posed by Health Canada are considered a formality as Plasm Pharmaceutical, continues to prepare for aContinue reading “Naturally Splendid Responds to Health Canada’s Information Request Notice”

Health Canada Requests Clinical Trial Protocol Details

– June 30, 2020 – Naturally Splendid Enterprises Ltd. (“Naturally Splendid”) (TSXV:NSP) (OTC:NSPDF) (Frankfurt:50N) is pleased to provide the following update in regards to the Clinical Trial Application (CTA) to Health Canada submitted May 17, 2020 as a treatment for Covid-19 with the target drug, Cavaltinib(TM). The Company continues to navigate the fast track CTA process withContinue reading “Health Canada Requests Clinical Trial Protocol Details”